CIK 0001635088 · Large accelerated filer
Roivant Sciences Ltd.
Sign in to watch- Ticker
- ROIV
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Mar 31
- Incorporated
- Bermuda
- Entity type
- operating
- EIN
- 981173944
- Phone
- 441-295-5950
- Business address
- 7TH FLOOR, 50 BROADWAY, LONDON, United Kingdom, SW1H 0DB
- 4 Grant or award Chief Accounting Officer acquired 29,173 shares (grant or award)
- 4 Shares withheld for taxes Director gave up 95 shares (to pay taxes)
- 4 Grant or award Director acquired 670 shares (grant or award)
- 4 Shares withheld for taxes Director gave up 94 shares (to pay taxes)
- 4 Open-market sale CEO sold 289,774 shares at $29.16 ($8,449,810)
- 4 Open-market sale Chief Accounting Officer sold 13,538 shares at $28.37 ($384,073)
- 4 Shares withheld for taxes President and Vant Chair gave up 160,035 shares (to pay taxes)
- 4 Shares withheld for taxes CEO gave up 358,510 shares (to pay taxes)
- 4 Shares withheld for taxes President & CIO gave up 217,321 shares (to pay taxes)
- 4 Open-market sale Director sold 70,000 shares at $27.45 ($1,921,500)
- 4 Shares withheld for taxes CFO gave up 1,546 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Accounting Officer gave up 14,526 shares (to pay taxes)
- 4 Planned sale President & Immunovant CEO sold 200,000 shares at $28.24 ($5,648,000)
- 4 Open-market sale Director sold 41,861 shares at $28.68 ($1,200,573)
- 4 Shares withheld for taxes CFO gave up 1,000 shares (to pay taxes)
- 4 Shares withheld for taxes President & Immunovant CEO gave up 7,051 shares (to pay taxes)
- 4 Planned sale President and Vant Chair sold 3,000,000 shares at an average $27.35 ($82,039,460)
- 4 Planned sale President & Immunovant CEO sold 200,000 shares at $26.49 ($5,298,000)
- 4 Open-market sale Director sold 1,225,784 shares at an average $26.64 ($32,658,518)
- 4 Open-market sale Director sold 1,225,784 shares at an average $26.64 ($32,658,518)
Page 4 of 26 · 511 filings